Biomedical and Biochemical Basis of Neurodegenerative Diseases

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 907

Special Issue Editor

Special Issue Information

Dear Colleagues,

In most brain-related diseases, neurodegeneration has been shown to be the primary pathophysiological alteration, and several different neurological conditions are referred to as neurodegenerative diseases. Memory, cognition, behavior, sensory function, and/or motor function are all negatively impacted by the degeneration of neural networks and the loss of neurons, which are incapable of efficiently renewing themselves because they are terminally differentiated. This leads to the breakdown of the fundamental communication circuitry. An individual may exhibit more than one neurodegenerative disease process, and the protein abnormalities that characterize neurodegenerative disorders might exist before the beginning of clinical symptoms. Currently, diagnostic biomarkers are unavailable, with the exception of rare instances in which the condition may be demonstrated to be caused by a causal genetic mutation. In addition to the diagnosis, the neurodegenerative diseases field needs new clinical, pathological, pharmacological, and genetic research. Instead, the age of onset, the sex of patient, the duration of symptoms, clinical diagnosis, the clinical markers of disease severity, the density and distribution of different pathologic processes, and the pharmacogenetic and pharmacokinetic characteristics of treatment should be investigated to achieve an increasingly better management of individual patients.

This proposed Special Issue aims to collect studies that provide clinical, biochemical, and therapeutic evidence on neurodegenerative diseases. In particular, we welcome original research articles and reviews, including but not limited to the following topics:

  • The biochemistry of neurodegenerative diseases.
  • The clinical basis of neurodegenerative diseases.
  • The genetics of neurodegenerative diseases.
  • Genetic influence on drug pharmacokinetics and pharmacodynamics in neurodegenerative diseases.
  • Combining therapeutic drug monitoring (TDM) with genetics in neurodegenerative diseases treatment.
  • Personalized medicine in neurodegenerative diseases.
  • Sex differences in neurodegenerative diseases.

Dr. Sarah Allegra
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurodegeneration
  • personalized medicine
  • biomarkers
  • diagnosis
  • treatment

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 2276 KiB  
Article
A Novel RP-UHPLC-MS/MS Approach for the Determination of Tryptophan Metabolites Derivatized with 2-Bromo-4′-Nitroacetophenone
by Timotej Jankech, Ivana Gerhardtova, Petra Majerova, Juraj Piestansky, Lubica Fialova, Josef Jampilek and Andrej Kovac
Biomedicines 2024, 12(5), 1003; https://doi.org/10.3390/biomedicines12051003 - 2 May 2024
Viewed by 562
Abstract
Many biologically active metabolites of the essential amino acid L-tryptophan (Trp) are associated with different neurodegenerative diseases and neurological disorders. Precise and reliable methods for their determination are needed. Variability in their physicochemical properties makes the analytical process challenging. In this case, chemical [...] Read more.
Many biologically active metabolites of the essential amino acid L-tryptophan (Trp) are associated with different neurodegenerative diseases and neurological disorders. Precise and reliable methods for their determination are needed. Variability in their physicochemical properties makes the analytical process challenging. In this case, chemical modification of analyte derivatization could come into play. Here, we introduce a novel fast reversed-phase ultra-high-performance liquid chromatography (RP-UHPLC) coupled with tandem mass spectrometry (MS/MS) method for the determination of Trp and its ten metabolites in human plasma samples after derivatization with 2-bromo-4′-nitroacetophenone (BNAP). The derivatization procedure was optimized in terms of incubation time, temperature, concentration, and volume of the derivatization reagent. Method development comprises a choice of a suitable stationary phase, mobile phase composition, and gradient elution optimization. The developed method was validated according to the ICH guidelines. Results of all validation parameters were within the acceptance criteria of the guideline, i.e., intra- and inter-day precision (expressed as relative standard deviation; RSD) were in the range of 0.5–8.2% and 2.3–7.4%, accuracy was in the range of 93.3–109.7% and 94.7–110.1%, limits of detection (LODs) were in the range of 0.15–9.43 ng/mL, coefficients of determination (R2) were higher than 0.9906, and carryovers were, in all cases, less than 8.8%. The practicability of the method was evaluated using the blue applicability grade index (BAGI) with a score of 65. Finally, the developed method was used for the analysis of Alzheimer’s disease and healthy control plasma to prove its applicability. Statistical analysis revealed significant changes in picolinic acid (PA), anthranilic acid (AA), 5 hydroxyindole-3-acetic acid (5-OH IAA), and quinolinic acid (QA) concentration levels. This could serve as the basis for future studies that will be conducted with a large cohort of patients. Full article
(This article belongs to the Special Issue Biomedical and Biochemical Basis of Neurodegenerative Diseases)
Show Figures

Figure 1

Back to TopTop